Thimerosal exposure and increased risk for diagnosed tic disorder in the United States: a case-control study

David A. GEIER\(^1\), Janet K. KERN\(^1\), Brian S. HOOKER\(^2\), Paul G. KING\(^3\), Lisa K. SYKES\(^3\), Kristin G. HOMME\(^4\), Mark R. GEIER\(^1\)

\(^{1}\) Institute of Chronic Illnesses, Inc., 14 Redgate Ct, Silver Spring, MD, USA
\(^{2}\) Associate Professor of Biology, Simpson University, Redding, CA, USA
\(^{3}\) CoMeD, Inc, Silver Spring, MD, USA
\(^{4}\) International Academy of Oral Medicine and Toxicology, ChampionsGate, FL, USA

ABSTRACT

A hypothesis testing, case-control study evaluated automated medical records for exposure to organic-Hg from Thimerosal-containing hepatitis B vaccines (TM-HepB) administered at specific intervals in the first six-months-of-life among cases diagnosed with a tic disorder (TD) or cerebral degeneration (CD) (an outcome not biologically plausibly linked to TM exposure) in comparison to controls; both cases and controls were continuously enrolled from birth (born from 1991–2000) within the Vaccine Safety Datalink (VSD) database. TD cases were significantly more likely than controls to have received increased organic-Hg from TM-HepB administered within the first month-of-life (odds ratio (OR)=1.59, \(p<0.00001\)), first two-months-of-life (OR=1.59, \(p<0.00001\)), and first six-months-of-life (OR=2.97, \(p<0.00001\)). Male TD cases were significantly more likely than male controls to have received increased organic-Hg from TM-HepB administered within the first month-of-life (OR =1.65, \(p<0.0001\)), first two-months-of-life (OR=1.64, \(p<0.0001\)), and first six-months-of-life (OR=2.47, \(p<0.05\)), whereas female TD were significantly more likely than female controls to have received increased organic-Hg from TM-HepB administered within the first six-months-of-life (OR=4.97, \(p<0.05\)). By contrast, CD cases were no more likely than controls to have received increased organic-Hg exposure from TM-HepB administered at any period studied within the first six-months-of-life. Although routine childhood vaccination is considered an important public health tool to combat infectious diseases, the present study associates increasing organic-Hg exposure from TM-HepB and the subsequent risk of a TD diagnosis.

KEY WORDS: ethylmercury, merthiolate, thiomersal, tic, tourette, vaccine

Introduction

Tic disorder (TD) is a neurodevelopmental disorder characterized by repetitive, involuntary movements and vocalizations called tics (Diagnostic and Statistical Manual of Mental Disorders – Fifth Edition; DSM-5, 2013; Roessner et al., 2011). TD includes Tourette’s syndrome, which is characterized by vocal as well as motor tics. Symptoms of TD typically begin in childhood, with the average onset between 3 and 9 years of age. Males are affected approximately three to four times more often than females. TD is considered a chronic condition that lasts a lifetime (National Institute of Neurological Disorders and Stroke, 2012). Psychopathology and co-morbidity occur in approximately 80–90% of clinical cohorts (Hariz et al., 2010). Two of the most common co-occurring psychiatric conditions are: (1) attention deficit/hyperactivity disorder (ADHD), occurring in about half the cases (Roessner et al., 2011; Freeman 2007) and (2) obsessive–compulsive disorder (OCD), also occurring in about half the cases (Roessner et al., 2011). Other common co-morbid conditions are depression, anxiety, and behavioral disorders (Hariz et al., 2010). Also reported are social difficulties and ritualistic behaviors such as counting, repeating, ordering, and arranging. Along with the dramatic rise in neurodevelopmental disorders in general in the last two decades, there has also been an increase in TD (Boyle et al., 2011; Cubo 2012). Although TD was once considered rare, today TD is considered the most common movement disorder, with 0.2–46.3% of schoolchildren experiencing tics during their lifetime (Cubo, 2012). To date, there is no consensus on the causes or contributing factors related to this increase. Many questions regarding the potential...
Determination of genetic inheritance and susceptibility, gene/environment interaction, and epigenetic or environmental factors to TD remain unanswered.

In 2000, investigators described the apparent first childhood case report of mercury (Hg) intoxication with TD as its only manifestation (Li et al., 2000). Subsequently, a series of epidemiological studies evaluated the potential relationship between exposure to organic-Hg from Thimerosal (TM) in childhood vaccines and the risk of a child being diagnosed with a TD (Thompson et al., 2007; Verstraeten et al., 2003; Andrews et al., 2004; Barile et al., 2012; Geier & Geier, 2005; Young et al., 2008). These previous studies employed various epidemiological methods such as case-control or cohort designs, and were conducted on children from several different countries. Each of these studies revealed a significant association between organic-Hg exposure from TM in childhood vaccines and the risk of a child being diagnosed with a TD, and several even observed a significant dose-dependent relationship between increasing organic-Hg exposure from TM-containing vaccines administered at specific intervals within the first year of life and the eventual risk of a child being diagnosed with a TD.

The purpose of the present study was to further evaluate the potential relationship between exposure to organic-Hg from TM-containing hepatitis B vaccines (TM-HepB) administered at specific intervals during the first six months of life, and the subsequent risk of a child being diagnosed with a TD, by conducting a case-control epidemiological study of automated medical records in the Vaccine Safety Datalink (VSD) database.

Materials and methods

The study protocol employed was approved by the US Centers for Disease Control and Prevention (CDC), the Institutional Review Board (IRB) of Kaiser Permanente North-West (KPNW), and the IRB of Kaiser Permanente Northern California (KPNC). The data was analyzed at the secure Research Data Center of the National Center for Health Statistics in Hyattsville, MD. The views expressed in this study do not necessarily reflect those of the CDC or those of Kaiser Permanente.

The VSD project was created in 1991 by the National Immunization Program (NIP) of the CDC. The VSD’s data collection and study methods have been previously described (Chen et al., 1997, 2000; Wassilak et al., 1995; Geier & Geier, 2004). The project links medical event information, specific vaccine history, and selected demographic information from the computerized databases of several health maintenance organizations (HMOs). The specific epidemiological methods of analysis employed in the present study were described in a recent study (Geier et al., 2013).

Determining the population at risk

A cohort of over 1 million infants enrolled in the VSD project (updated through the end of 2000) from KPNW, Kaiser Permanente Colorado (KPC), and KPNC was examined using SAS® software. The cohort examined was comprised of individuals who were HMO-enrolled from their date of birth and whose records specified their gender.

Determining Cases

The outcome files (inpatient and outpatient diagnoses) from this population were then reviewed to find the first instance of TD for each child as defined by the International Classification of Disease, 9th revision (ICD-9). The TD-associated ICD-9 diagnostic codes examined included: tic disorder, unspecified (307.20), transient tic disorder (307.21), chronic motor or vocal tic disorder (307.22), and Tourette’s disorder (307.23). If there were multiple instances of the same diagnosis in a child, only the first instance was counted. In addition, to ensure that exposure preceded the diagnosis of a TD, for vaccinated individuals diagnosed with a TD, only those individuals diagnosed with a TD following administration of the vaccines under study were included as cases in the present analyses (less than 10% of individuals diagnosed with a TD were excluded because of this criterion).

A total of 344 cases diagnosed with TD (males = 253, females = 91, male/female ratio = 2.8), born from 1991 through 2000, were identified. These individuals diagnosed with TD were evaluated to determine their mean age of initial diagnosis of TD ± standard deviation of mean age of initial diagnosis of TD (5.10±2.01 years-old).

In addition, the putative generally accepted biologically non-plausible linkage between TM exposure and a subsequent diagnosis of cerebral degeneration was examined as a control outcome. The outcome files (inpatient and outpatient diagnoses) from this population were reviewed to find the first instance of cerebral degeneration for each child defined as 330.xx or 331.xx by ICD-9 coding. If there were multiple instances of the same diagnosis in a child, only the first instance was counted. In addition, to ensure the potential for an association between exposure and outcome, for vaccinated individuals diagnosed with cerebral degeneration, only those individuals diagnosed with cerebral degeneration following administration of the vaccines under study were included as cases in the present analyses.

A total of 647 cases diagnosed with cerebral degeneration (males = 359, females = 288, male/female ratio = 1.25), born from 1991 through 2000, were identified. These individuals diagnosed with cerebral degeneration were evaluated to determine their mean age of initial diagnosis of TD ± standard error of mean age of initial diagnosis of cerebral degeneration (0.63±0.04 years-old).

Determining controls

In order to identify controls without a diagnosis of TD who would have only a minimal chance of subsequently receiving such a diagnosis, controls had to have been continuously enrolled from birth for at least 7.11 years (mean age of initial diagnosis of TD plus the standard deviation of mean age of initial diagnosis of TD). Applying
this follow-up criterion yielded a total of 28,016 controls without a TD diagnoses (males = 14,327, females = 13,689, male/female ratio = 1.05) born from 1991 through 1993.

In order to identify controls without a diagnosis of cerebral degeneration who would have only a minimal chance of subsequently receiving such a diagnosis, controls had to have been continuously enrolled from birth for at least 2.6 years (mean age of initial diagnosis of cerebral degeneration plus two times the standard deviation of mean age of initial diagnosis of cerebral degeneration). Applying this follow-up criterion yielded a total of 35,888 controls without a cerebral degeneration diagnoses (males = 69,426, females = 66,462, male/female ratio = 1.05) born from 1991 through 1998.

**Hepatitis B vaccine exposure**

The vaccine file for cases and controls was then reviewed to determine the exact dates of HepB administration. Those cases and controls receiving no doses of HepB were also included in the present study. Hg exposure was assigned as 12.5 microgram (µg) of organic-Hg per dose for those receiving a pediatric HepB or 0 µg of organic-Hg per dose for those receiving either combined haemophilus influenzae type b (Hib)-HepB or neither of the aforementioned vaccines. The Hg content of the vaccine doses was based upon the report of the Committee on Infectious Disease and Committee on Environmental Health of the American Academy of Pediatrics report of the TM content in US-licensed vaccines from 1999 (American Academy of Pediatrics 1999). Overall among the cases and controls, the maximum exposure to Hg from pediatric HepB was 37.5 µg of organic-Hg (from children receiving three doses of TM-HepB) administered within the first six months of life.

**Statistical analyses**

The Fisher’s exact test contained in the SAS® software was utilized for statistical analyses, and a two-sided p-value <0.05 was considered statistically significant. Three different levels of Hg exposure from TM-HepB were examined. In the first case-control experimental group (Experiment I), the data were examined to determine the frequency of exposure to 12.5 µg of organic-Hg from TM-HepB in the first month of life, in comparison to the frequency of 0 µg of organic-Hg from TM-free hepatitis B vaccine (TM-free-HepB) or no HepB in the first month of life, among cases and controls. In the second case-control experimental group (Experiment II), the data were examined to determine the frequency of receiving two TM-HepB within the first two months of life or a total of 25 µg of organic-Hg, in comparison to the frequency of receiving 0µg of organic-Hg from TM-free-HepB and/or no HepB in the first two months of life, among cases and controls. In the third case-control experimental group (Experiment III), the data were examined to determine the frequency of receiving three TM-HepB within the first six months of life, or a total of 37.5 µg of organic-Hg, in comparison to the frequency of receiving 0 µg of organic-Hg in the first sixth months of life, from TM-free-HepB and/or no HepB among cases and controls. In addition, because the ratio of males to females was 2.8, using the aforementioned exposures and exposure windows, additional separate analyses were completed where male cases were compared to male controls (Experiments IV–VI) and female cases were compared to female controls (Experiments VII–IX). Finally, using the aforementioned exposures and exposure windows, cases diagnosed with the putative non-biological plausibly linked TM-associated diagnosis of cerebral degeneration, a medical condition that is generally accepted as biologically not plausibly linked to TM exposure was compared to controls (Experiments X–XII). The overall null hypothesis for each of these case-control experimental groups was that there would be no difference in the frequency of exposure to organic-Hg doses from TM-HepB between the cases and the controls.

**Results**

Table 1 displays the relationship between cases diagnosed with a TD and controls receiving increasing doses of organic-Hg from TM-HepB at several specific points within the first six months of life. Experiment I documented that cases diagnosed with TD were significantly more likely (odds ratio = 1.59, p<0.0001) than controls to

| Group Examined | Number of Cases Diagnosed with a TD (%) | Number of Controls without a TD Diagnosis (%) | Odds Ratio (95% CI) | p-value |
|----------------|-----------------------------------------|-----------------------------------------------|---------------------|---------|
| Experiment I   |                                         |                                               |                     |         |
| 12.5 µg organic-Hg within 1st month | 151 (43.90) | 9,222 (32.92) | 1.59 (1.29–1.98) | <0.00001 |
| 0 µg organic-Hg within 1st month | 193 (56.10) | 18,794 (67.08) |                     |         |
| Experiment II  |                                         |                                               |                     |         |
| 25 µg organic-Hg within first 2 months | 151 (44.54) | 9,236 (33.62) | 1.59 (1.28–1.97) | <0.00001 |
| 0 µg organic-Hg within first 2 months | 188 (55.46) | 18,233 (66.38) |                     |         |
| Experiment III |                                         |                                               |                     |         |
| 37.5 µg organic-Hg within first 6 months | 33 (76.74) | 1,292 (52.63) | 2.97 (1.46–6.05) | 0.005   |
| 0 µg organic-Hg within first 6 months | 10 (23.26) | 1,163 (47.37) |                     |         |
have received 12.5 µg of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB or no HepB within the first month of life. Experiment II documented that cases diagnosed with a TD were significantly more likely (odds ratio = 1.59, p<0.0001) than controls to have received 25 µg of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB and/or no HepB within the first two months of life. Finally, in Experiment III, cases diagnosed with a TD were significantly more likely (odds ratio = 2.97, p<0.005) than controls to have received 37.5 µg of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB and/or no HepB within the first six months of life.

Tables 2 and 3 present the relationship between males cases diagnosed with a TD in comparison to male controls and female cases diagnosed with a TD in comparison to female controls receiving increasing doses of organic-Hg from TM-HepB at several specific points within the first six months of life. Experiment IV documented that male cases diagnosed with a TD were significantly more likely (odds ratio = 1.65, p<0.001) than male controls to have received 12.5 µg of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB or no HepB within the first month of life. Experiment V documented that male cases diagnosed with a TD were significantly more likely (odds ratio = 1.64, p<0.001) than male controls to have received 25 µg of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB and/or no HepB within the first two months of life. Finally, in Experiment VI, male cases diagnosed with a TD were significantly more likely (odds ratio = 2.47, p<0.05) than male controls to have received 37.5 µg of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB and/or no HepB within the first six months of life. By contrast, only females diagnosed with a TD in comparison to female controls were significantly more likely (odds ratio = 4.97, p<0.05) to have received 37.5 µg of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB and/or no HepB within the first six months of life (Experiment IX).

Table 4 summarizes the relationship between cases diagnosed with the cerebral degeneration, a medical condition that is not felt to be biologically linked to TM exposure, in comparison to controls receiving increasing doses of organic-Hg from TM-HepB at several specific points within the first six months of life. The results revealed that cases diagnosed with cerebral degeneration in comparison to controls were actually significantly less likely

---

**Table 2.** A summary of exposure to organic-Hg from Thimerosal-containing hepatitis B vaccine administration among male cases diagnosed with TD in comparison to male controls.

| Group Examined | Number of Male Cases Diagnosed with TD (%) | Number of Male Controls without a TD Diagnosis (%) | Odds Ratio (95% CI) | p-value |
|----------------|-------------------------------------------|-----------------------------------------------|---------------------|---------|
| Experiment IV  | 12.5 µg organic mercury within 1st month  | 113 (44.66)                                   | 4,697 (32.78)       | 1.65 (1.29–2.12) | <0.0001 |
|                | 0 µg organic mercury within 1st month     | 140 (55.34)                                   | 9,630 (67.22)       |         |         |
| Experiment V   | 25 µg organic mercury within first 2 months | 113 (45.20)                                   | 4,704 (33.51)       | 1.64 (1.27–2.10) | <0.0001 |
|                | 0 µg organic mercury within first 2 months | 137 (54.80)                                   | 9,333 (66.49)       |         |         |
| Experiment VI  | 37.5 µg organic mercury within first 6 months | 22 (73.33)                                   | 640 (52.72)         | 2.47 (1.09–5.58) | <0.05   |
|                | 0 µg organic mercury within first 6 months | 8 (26.67)                                    | 574 (47.28)         |         |         |

**Table 3.** A summary of exposure to organic-Hg from Thimerosal-containing hepatitis B vaccine administration among female cases diagnosed with TD in comparison to female controls.

| Group Examined | Number of Female Cases Diagnosed with TD (%) | Number of Female Controls without a TD Diagnosis (%) | Odds Ratio (95% CI) | p-value |
|----------------|--------------------------------------------|-----------------------------------------------|---------------------|---------|
| Experiment VII | 12.5 µg organic mercury within 1st month   | 38 (41.76)                                    | 4,525 (33.06)       | 1.45 (0.95–2.21) | 0.09    |
|                | 0 µg organic mercury within 1st month      | 53 (58.24)                                    | 9,164 (66.94)       |         |         |
| Experiment VIII| 25 µg organic mercury within first 2 months | 38 (42.70)                                    | 4,532 (33.74)       | 1.46 (0.96–2.23) | 0.09    |
|                | 0 µg organic mercury within first 2 months | 51 (57.30)                                    | 8,900 (66.26)       |         |         |
| Experiment IX  | 37.5 µg organic mercury within first 6 months | 11 (84.61)                                   | 652 (52.54)         | 4.97 (1.1–22.5) | <0.05   |
|                | 0 µg organic mercury within first 6 months | 2 (15.39)                                    | 589 (47.46)         |         |         |
Table 4. A summary of exposure to organic-Hg from Thimerosal-containing hepatitis B vaccine administration among cases diagnosed with cerebral degeneration in comparison to controls.

| Group Examined | Number of Cases Diagnosed with Cerebral Degeneration (%) | Number of Controls without a Cerebral Degeneration Diagnosis (%) | Odds Ratio (95% CI) | p-value |
|---------------|----------------------------------------------------------|-----------------------------------------------------------------|---------------------|---------|
| Experiment X  | 12.5 µg organic-Hg within 1st month                        | 62,637 (46.09)                                                  | 0.43 (0.36–0.52)    | <0.00001|
|               | 0 µg organic-Hg within 1st month                           | 73,252 (53.91)                                                  |                     |         |
| Experiment XI | 25 µg organic-Hg within first 2 months                     | 62,637 (46.63)                                                  | 0.42 (0.36–0.51)    | <0.00001|
|               | 0 µg organic-Hg within first 2 months                     | 71,694 (53.37)                                                  |                     |         |
| Experiment XII| 37.5 µg organic-Hg within first 6 months                   | 13,145 (71.86)                                                  | 0.25 (0.18–0.35)    | <0.005  |
|               | 0 µg organic-Hg within first 6 months                     | 5,148 (28.14)                                                  |                     |         |

to receive increasing doses of organic-Hg from TM-HepB in comparison to 0 µg of organic-Hg from TM-free-HepB and/or no HepB within the first, second, and sixth months of life (Experiments X–XII).

**Discussion**

Consistent with the aforementioned six epidemiological studies that found a significant relationship between organic-Hg exposure from TM in childhood vaccines and the risk of a child being diagnosed with a TD (Thompson et al., 2007; Verstraeten et al., 2003; Andrews et al., 2004; Barile et al., 2012; Geier & Geier 2005; Young et al., 2008), the results from the present study show a significant association between increasing organic-Hg exposure from TM-HepB administered at specific interval within the first six months of life and the eventual risk of child receiving a TD diagnosis. Also, consistent with the aforementioned epidemiological studies that showed a dose-dependent relationship between increasing organic-Hg exposure from TM in childhood vaccines and increasing risk of a child being diagnosed with a TD, the results of the present study showed that increased organic-Hg exposure from TM-HepB was associated with an increased eventual risk of a child receiving a TD diagnosis.

The biological plausibility of a significant association between organic-Hg exposure from TM in childhood vaccines and the risk of a TD diagnosis is supported by the fact that TM is known to rapidly dissociate into ethyl-Hg chloride, ethyl-Hg hydroxide, and sodium thiosalicylate in saline solutions (Tan & Parkin, 2000). In addition, it was observed in human infants that administering TM-containing vaccines significantly increased an infant’s blood- and hair-Hg levels, with some infants having total blood- and hair-Hg levels in excess of the safety limit adopted by the US Environmental Protection Agency (EPA) (Stajich et al., 2000; Pichichero et al., 2008, 2009; Redwood et al., 2001; Marques et al., 2007). It was even observed by investigators that TM administration to infant monkeys mimicking the US early childhood vaccination schedule of the 1990s resulted in significant levels of Hg being present in the brain (Burbacher et al., 2005), and that ethyl-Hg species are actively transported across neuronal cellular membranes (Zimmermann et al., 2013; Wehe et al., 2014).

Once any form of Hg enters the brain, it immediately has a plethora of negative effects, one of which is axonal degeneration, particularly of large caliber axons that tend to connect distant parts of the brain (Kern et al., 2012, 2013). Unfortunately, once these long-range axons are destroyed, they are unlikely to be regenerated. In other words, the shorter the distance between the regeneration site and its distal target, the more successful the regeneration of a nerve is likely to be (Fawcett, 1992). Overall, postnatally damaged mature neuronal axons only regenerate for very short distances in the central nervous system (CNS). Because long-range axons cannot be regenerated, short-range axons result when long-range axons are destroyed. It has been shown that following damage to connected brain regions, the brain undergoes an adaptive response which includes reactive axonal sprouting and an overproduction of dendrites (Jones, 1999; Jones et al., 1992).

To this point, researchers have shown long-range axon loss (with subsequent long-range underconnectivity) along with short-range overconnectivity in subjects diagnosed with a TD (Church et al., 2009; Liu et al., 2013; Neuner et al., 2010). Church et al. (2009), for example, examined functional connectivity in subjects diagnosed with a TD and theorized that the decreased long-range functional connectivity between control regions in the brain (e.g., between the dorsolateral prefrontal cortex and the posterior parietal cortex), along with the short-range overconnectivity (e.g., between the anterior and the dorsolateral prefrontal cortices) may explain the inability to control unwanted behaviors in subjects diagnosed with a TD.

This evidence of long-range underconnectivity and short-range overconnectivity found in subjects diagnosed with a TD is also characteristic of ADHD and autism.
spectrum disorder (ASD) (Fair et al., 2007; Wang et al., 2009; Castellanos et al., 2008; Wass, 2011). In addition, TD shares additional symptomatology with ADHD and ASD, including issues with attention, impulsivity, repetitive behaviors, social impairment, anxiety, obsessive compulsive behaviors, and depression (Grzadzinski et al., 2011; Kern et al., 2015; National Institute of Neurological Disorders and Stroke, 2013; Hariz et al., 2010). Finally, consistent with the significant association observed between organic-Hg exposure from TM-containing vaccine administration and the risk of a child being diagnosed with a TD (Thompson et al., 2007; Verstraeten et al., 2003; Andrews et al., 2004; Barile et al., 2012; Geier & Geier, 2005; Young et al., 2008), it was observed in a series of previous epidemiological studies that a significant association was observed between organic-Hg exposure from TM-containing vaccine administration at specific intervals within the first year of life and the eventual risk of child being diagnosed with ADHD or ASD (Young et al., 2008; Geier & Geier, 2005, 2006; Geier et al., 2013).

Strengths/limitations

As described by investigators from the CDC and US Food and Drug Administration (FDA), products, such as vaccines, which are intended as disease-preventive interventions given to healthy people, must be held to a high standard of safety assurance (Ellenberg & Braun, 2002; DeStefano et al., 2001). However, those investigators reported that the study of vaccine risks is more complex than for therapeutic products because exposure is virtually universal for many vaccines, ensuring the chance occurrence of many adverse outcomes in temporal association with vaccines. As a result, those investigators identified the utility of using the VSD, a consortium of HMOs to rigorously evaluate vaccine-associated risks in hypothesis testing studies.

The strength of the VSD is revealed in the present study because the observations made were based on a retrospective assessment of prospectively collected medical records. Any potential independent variables that might have been associated with either enrollment or healthcare-seeking behaviors were moot because all cases were required to be enrolled from birth until a TD was diagnosed, and all controls had to be enrolled from birth for a time period sufficient to minimize the chance that a TD diagnosis would emerge during follow-up. In addition, vaccinated cases diagnosed with a TD were specifically evaluated to ensure that only those vaccinated cases diagnosed with a TD following their HepB vaccine administration were considered in the present analyses.

That the VSD data were collected independently of the present study is another strength of the study. The VSD data records were collected as part of the routine healthcare that patients received through participation with their respective HMOs, and as such, the healthcare providers were not contemplating any possible associations between vaccine exposures and potential health outcomes. An additional strength of the present study was that the specific methods employed to evaluate the hypothesis were also able to exploit recommendations for the timing of vaccine administration that varied widely. Specifically, differences in cumulative doses of organic-Hg received at specific intervals during the infant period were evaluated based upon the wide-ranging recommendations for routine HepB administration. In 1991, the Advisory Committee on Immunization Practices (ACIP) recommended that infants should receive their HepB doses as follows: first dose between birth and 2 months of age, second dose between 1 and 4 months of age, and third dose between 6 and 18 months of age (CDC, 1991). Importantly, the differences in organic-Hg exposures observed in all experiments of the present study were not the result of a small group of children receiving anomalous exposures to vaccines. Instead, the experiments assessed varying levels of organic-Hg exposure which resulted from the varying windows recommended for administration of HepB during the first 18 months of life.

A further strength of the present study was that adequate follow-up was employed to ensure that most subjects in the control group were unlikely to be subsequently diagnosed with a TD. This was achieved by setting an a priori requirement that, to be a valid control-cohort member, a child had to be continuously enrolled in the VSD from birth until the child attained the mean age of initial TD diagnosis plus the standard deviation for that mean age, which was 7.11 years of age based on the distribution statistics for the cases. Statistically setting the follow-up age for the control group in this manner assured a less than a 16% chance that some of the controls might subsequently be diagnosed with a TD. Ideally, a longer follow-up period would have further reduced this misclassification risk. However, the limitations on the VSD patient data records that were available for review precluded a longer follow up period because the VSD data available for examination ended in 2000. It is important to ensure that most controls will have little risk of subsequently being diagnosed, because for outcomes that have a wide onset window, like TD, the statistical “noise” in the exposure signal will be minimized when a sufficient follow-up is ensured.

By reducing the length of follow-up, and hence introducing greater uncertainty as to the correct diagnostic status of the controls, the magnitude of the observed adverse effects associated with exposure would be reduced, which in turn would bias the results toward the null hypothesis. For example, by requiring that those in the control group only having to be continuously enrolled in the VSD from birth until they were at least 5.10 years-old (the mean age of initial TD diagnosis), those in the TD case group were no longer significantly more likely (odds ratio = 1.42, p<0.40) than controls to have received 37.5 µg of organic-Hg from TM-HepB within the first six months of life than 0 µg of organic-Hg from TM-free-HepB in the first six months of life.

The results of the present study may have a number of potential limitations. It is theoretically possible that
the observed results may have occurred from unknown biases or confounders present in the datasets examined. However, this seems unlikely because the putative biologically non-plausible linkage between TM exposure and a subsequent diagnosis of cerebral degeneration was examined as a control outcome, using the same VSD database and methodology employed for TD. No similar patterns of significant associations were observed for these outcomes. Moreover, the diagnosed cases having TM exposure that is generally accepted as being not biologically linked to a diagnosis cerebral degeneration were significantly less likely than controls to receive increasing organic-Hg exposure in comparison to TM-free-HepB or no HepB administered at specific intervals within the first six months of life. The observed apparent protective effect of TM on the risk of an individual being diagnosed with cerebral degeneration suggests that a “healthy vaccine effect” was present in our data. As described previously by investigators from the CDC (Fine & Chen, 1992), confounding of this sort is a general problem for studies of adverse reactions to prophylactic interventions, as they may be withheld from some individuals precisely because they are already at high risk of the adverse event, and as consequence studies that fail to control adequately for such confounding factors are likely to underestimate the risk of adverse events attributable to vaccination. Since this phenomenon is apparent in the data examined, the significantly increased odds ratios observed for increasing organic-Hg exposure among cases diagnosed with TD are probably underestimates of the true extent of the relationship between organic-Hg exposure from TM and the TD outcome studied.

Another theoretical limitation of the present study is that the results observed for TD may be due to statistical chance. However, such a possibility would be unlikely given the limited number of statistical tests performed, the highly significant results observed, and the consistency in the direction and magnitude of the results observed.

Still other theoretical limitations of the present study include the possibilities that some of the children in the cohorts may have had subtle neurological dysfunction that was not recorded in the medical record; healthcare providers may have misdiagnosed some individuals; or some vaccine exposures may not have been appropriately classified. These possibilities should not have affected the results significantly because both cases and controls should have been affected similarly. Moreover, misclassification would tend to bias the results toward the null hypothesis, since such effects would result in individuals being placed in the wrong exposure and/or outcome categories, and this would result in decreased statistical power to determine true potential exposure-outcome relationships.

Another potential limitation of the present study is that exposures to other sources of Hg were not evaluated. The children examined in the present study very likely incurred other exposures to Hg from other TM-containing vaccines, breastfeeding, formula feeding, and, possibly, dental amalgams, fish, or other environmental sources. The limitation of not being able to associate other vaccine-related Hg exposures was one of the limitations specifically imposed by the CDC staff who assembled our VSD dataset. While other sources of Hg may play a significant role in the pathogenesis of TD, such exposures, which were not accounted for in this study, would actually tend to bias the results towards the null hypothesis by confounding the Hg exposure classifications examined. For example, individuals classified as having lower organic-Hg exposure from TM-containing vaccines may have actually received high doses of Hg from other sources, and individuals having higher organic-Hg exposure from TM-containing vaccines may have actually received low doses of Hg from other sources, with the net result tending to minimize the magnitude of the associations observed.

An additional potential limitation of the present study is that the individuals examined participated with different HMOs, and, as such, HMO differences may account for some of the phenomena observed. This phenomena would seem to be unlikely because each HMO studied followed similar national ACIP guidelines for HepB vaccine administration and used similar ICD-9 coding to medically document the outcomes of individuals. In addition, because of the manner in which the CDC staff provided us our VSD datasets, it was not possible to identify the specific HMOs that each individual was enrolled. Despite this limitation in our VSD datasets, we believe that it would not necessarily be prudent to stratify the data by HMO, because to do so would assume that the differences in population sizes for each HMO should be given equal weight with respect to their potential impact on the phenomena observed, despite each HMO having varying degrees of statistical power to detect the phenomena observed based upon the size of the HMO population.

Finally, the current study suffers from the potential limitation that the analyses were not conducted to explore the precise timing and cumulative doses of organic-Hg from all TM-containing childhood vaccines associated with maximum potential adverse consequences. In future studies, it would be worthwhile to explore these precise timing and cumulative-dose phenomena. In addition, evaluating other neurodevelopmental outcomes, as well as other covariates such as gender, race, birth weight, etc., that may affect the magnitude of the adverse effects found, would be valuable.

Conclusion
In summary, using a hypothesis-testing, epidemiological methodology applied to the VSD database, organic-Hg exposure from TM-containing childhood vaccines was determined to be a significant risk factor for the subsequent diagnosis of TD. Six previous epidemiological studies support this finding (Thompson et al., 2007; Verstraeten et al., 2003; Andrews et al., 2004; Barile et al., 2012; Geier & Geier, 2005; Young et al., 2008). In addition, this study, consistent with previous epidemiological
studies, shows a dose dependent effect (i.e., the greater the exposure to Hg, the greater the chances of having a TD diagnosis).

As mentioned previously, since Hg may accumulate in the brain and other tissues, the combined exposure from different sources is a serious concern, especially in the face of an underlying chronic environmental exposure that appears to be increasing (Kern et al., 2011; Laks, 2009). Additive effects from different sources could potentially increase a child’s Hg exposure from a subclinical to a clinical level, with neurodevelopmental consequences. Thus, every preventable source of Hg exposure should be evaluated and avoided. Routine childhood vaccination is considered an important public health tool to reduce the morbidity and mortality associated with infectious diseases (Geier & Geier, 2002). However, based on data, including the results of the present study that show an association between administration of a TM-containing vaccine and adverse neurodevelopmental outcomes, it is also a public health imperative to end the addition of organic-Hg to vaccines in the form of TM used as a preservative.

Acknowledgements

This study was supported by the non-profit Institute of Chronic Illnesses, Inc and the non-profit CoMed, Inc. This study was also supported the Seltz Foundation and the Dwoaskin Family Foundation, but they were not involved in the design and conduct of the study, in the collection analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.

Competing Interests

All the authors have been involved in vaccine/biologic litigation, but none involving Thimerosal exposure and tic disorder.

REFERENCES

American Academy of Pediatrics. (1999). Thimerosal in vaccines – An interim report to clinicians. American Academy of Pediatrics. Committee on Infectious Diseases and Committee on Environmental Health. Pediatrics 104: 570–574.

American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (Fifth edition). Washington, DC, American Psychiatric Association.

Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B. (2004). Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatr 114: 584–591.

Barile JP, Kuperminc GP, Weintrob ES, Mink JW, Thompson WW. (2012). Thimerosal exposure in early life and neuropsychological outcomes 7–10 years later. Journal of Pediatric Psychology 37: 106–118.

Boyle CA, Boutel S, Schieve LA, Cohen RA, Blumberg SJ, Yeanin-Allsopp M, Visser S, Kogan MD. (2011). Trends in the prevalence of developmental disabilities in US children, 1997–2008. Pediatrics 127(6): 1034–1042.

Burbacher TM, Shen DD, Liberato N, Grant KS, Cernichiari E, Clarkson T. (2005). Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ Health Perspect 113: 1015–1021.

Castellanos FX, Margulies DS, Kelly C, Uddin LQ, Ghaffari M, Kirsch A, Shaw D, Shehzad Z, Di Martino A, Bivuk B, Sonuga-Barke EJ, Rotrosen J, Adler LA, Milham MP. (2008). Cingulate-precuneus interactions: a new locus of dysfunction in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 63(3): 332–337.

Centers for Disease Control. (1991). Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP, MMWR Recomm Rep 40(RR-13): 1–23.

Chen RT, DeStefano F, Davis RL, Jackson LA, Thompson RS, Mullooly JP, Black SB, Shinifield HR, Vadheim CM, Ward Ji, Marcy SM. (2000). The vaccine safety datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 78(2): 166–194.

Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinifield HR, Vadheim CM, Marcy SM, Ward Ji, Wise RP, Wassilak SG, Hadler SC. (1997). Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 99(6): 765–773.

Church JA, Fair DA, Dosenbach NU, Cohen AI, Miezien FM, Petersen SE, Schlaggar BL. (2009). Control networks in paediatric Tourette syndrome show immature and anomalous patterns of functional connectivity. Brain 132: 225–238.

Cubo E. (2012). Review of prevalence studies of tic disorders: methodological caveats. Tremor Other Hyperkinet Mov (N Y) 2 pii: tre-02-63-149-1.

DeStefano F, Vaccine Safety Datalink Research Group. (2001). The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf 10: 403–406.

Ellenberg SS, Braun MM. (2002). Monitoring the safety of vaccinees: assessing the risks. Drug Saf 25: 145–152.

Fair DA, Dosenbach NU, Church JA, Cohen AL, Brahmbhatt S, Miezien FM, Barch DM, Raichle ME, Petersen SE, Schlaggar BL. (2007). Development of distinct control networks through segregation and integration. Proc Natl Acad Sci U S A 104: 13307–13312.

Fawcett JW. (1992). Intrinsic neuronal determinants of regeneration. Trends in Neurosci 15: 5–8.

Fine PE, Chen RT. (1992). Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 136: 121–135.

Freeman RD, Tourette Syndrome International Database Consortium. (2007). Tic disorders and ADHD: answers from a world-wide clinical dataset on Tourette syndrome. Eur Child Adolesc Psychiatry 16(Suppl 1): 11–23.

Geier MR, Geier DA. (2002). The state of polio vaccination in the world: the case for continuing routine vaccination. Toxicol Mech Methods 12: 221–228.

Geier DA, Geier MR. (2004). A review of the Vaccine Adverse Event Reporting System database. Expert Opin Pharmacother 5: 691–698.

Geier DA, Geier MR. (2005). A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis. Med Sci Monit 11: CR160–CR170.

Geier DA, Geier MR. (2006). A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett 27(4): 401–413.

Geier DA, Hooker BS, Kern JK, King PG, Sykes LK, Geier MR. (2013). A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States. Transl Neurodegener 2: 25.

Grazzini R, Di Martino A, Brady E, Mairena MA, O’Neale M, Petkova E, Lord C, Castellanos FX. (2011). Examining autistic traits in children with ADHD: a blinded study measuring urinary porphyrins. Interdisciplinary Toxicology 2015, Vol. 8(2): 68–76. Full text also available online at PubMed Central 75
Kern JK, Geier DA, Sykes NK, Geier MR, Deth RC. (2015). Are ASD and ADHD a continuum? A comparison of pathophysiological similarities between the disorders. J Atten Disord 19(9): 805–27.

Kern JK, Haley BE, Geier DA, Sykes NK, King PG, Geier MR. (2013). Thimerosal exposure and the role of sulfur chemistry and thiol availability in autism. Int J Environ Res Public Health 10: 3771–3800.

Laks DR. (2009). Assessment of chronic mercury exposure within the U.S. population, National Health and Nutrition Examination Survey, 1999–2006. Biometals 22: 1103–1114.

Li AM, Chan MM, Leung TF, Cheung RC, Lam CW, Fok TF. (2000). Mercury intoxication present with tics. Arch Dis Childhood 83: 174–175.

Liu Y, Mao W, Wang J, Gao P, Yin G, Zhang L, Xu C, Ji Z, Yu T, Sabel BA, He H, Peng Y. (2013). Structural abnormalities in early Tourette syndrome children: a combined voxel-based morphometry and tract-based spatial statistics study. PLoS One 8(9): e76105.

Marques RC, Dórea JG, Fonseca MF, Bastos WR, Malm O. (2007). Hair mercury in breast-fed infants exposed to thimerosal-preserved vaccines. Eur J Pediatr 166(9): 935–941.

National Institute of Neurological Disorders and Stroke. National Institutes of Health. Tourette Syndrome Fact Sheet 2013 [updated 10/19/2012]. Available from [accessed on: 4/12/2014]: http://www.ninds.nih.gov/disorders/tourette/detail_tourette.htm#220453231.

Neuner I, Kupriyanova Y, Stöcker T, Huang R, Posansky O, Schneider F, Tittgemeyer M, Shah NJ. (2010). White-matter abnormalities in Tourette syndrome extend beyond motor pathways. Neuroimage 51(3): 1184–1193.

Pichichero ME, Gentile A, Giglio N, Umido V, Clarkson T, Cernichiari E, Zareba G, Gotelli C, Gotelli M, Yan L, Treanor J. (2008). Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics 121(2): e208–e214.

Pichichero ME, Gentile A, Giglio N, Alonso MM, Fernandez Mentaberry MV, Zareba G, Clarkson T, Gotelli C, Gotelli M, Yan L, Treanor J. (2009). Mercury levels in premature and low birth weight newborn infants after receipt of thimerosal-containing vaccines. J Pediatr 155(4): 495–499.

Redwood L, Bernard S, Brown D. (2001). Predicted mercury concentrations in hair from infant immunizations: cause for concern. Neurotoxicology 22: 691–697.

Roessner V, Hoekstra PJ, Rothenberger A. (2011). Tourette’s disorder and other tic disorders in DSM-5: a comment. Eur Child Adolesc Psychiatry 20: 71–74.

Stajich GV, Lopez GP, Harry SW, Sexson WR. (2000). Iatrogenic exposure to mercury after hepatitis B vaccination in preterm infants. J Pediatr 136: 679–681.

Tan M, Parkin JE. (2000). Route of decomposition of thiomersal (thimerosal). Int J Pharm 208: 23–34.

Thompson WW, Price C, Goodson B, Shay DK, Benson P, Hinrichsen VL, et al. (2007). Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 357: 1281–1292.

Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT; Vaccine Safety Datalink Team. (2003). Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 112: 1039–1048.

Wang L, Zhu C, He Y, Zang Y, Cao Q, Zhang H, Zhong Q, Wang Y. (2009). Altered small-world brain functional networks in children with attention-deficit/hyperactivity disorder. Hum Brain Mapp 30: 638–649.

Wass S. (2011). Distortions and disconnections: disrupted brain connectivity in autism. Brain Cogn 75: 18–28.

Wassilak SG, Glasser JW, Chen RT, Hadler SC. (1995). Utility of large-linked databases in vaccine safety, particularly in distinguishing independent and synergistic effects. The Vaccine Safety Datalink Investigators. Ann NY Acad Sci 754: 377–382.

Wehe CA, Pieper I, Holtkamp M, Thyszen GM, Spierling M, Schwedtke T, Karst U. (2014). On-line species-unspecific isotope dilution analysis in the picomolar range reveals the time- and species-depending mercury uptake in human astrocytes. Anal Bioanal Chem 406(7): 1909–1916.

Young HA, Geier DA, Geier MR. (2008). Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink. J Neurol Sci 271: 110–118.

Zimmermann LT, Santos DB, Naime AA, Leal RB, Dórea JG, Barbosa F Jr, Aschner M, Rocha JB, Farina M. (2013). Comparative study on methyl- and ethyl-mercury-induced toxicity in C6 glioma cells and the potential role of LAT-1 in mediating mercurial-thiol complexes uptake. Neurotoxicology 38: 1–8.